Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 4 years, with Q4 2025 value amounting to $22.5 million.

  • Arrowhead Pharmaceuticals' Interest Expenses rose 396.84% to $22.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $90.2 million, marking a year-over-year increase of 8551.95%. This contributed to the annual value of $89.4 million for FY2025, which is 17621.48% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Interest Expenses is $22.5 million, which was up 396.84% from $21.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Interest Expenses high stood at $24.4 million for Q2 2025, and its period low was $2.8 million during Q4 2022.
  • In the last 4 years, Arrowhead Pharmaceuticals' Interest Expenses had a median value of $7.2 million in 2024 and averaged $12.5 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first plummeted by 124.08% in 2024, then surged by 37864.15% in 2025.
  • Arrowhead Pharmaceuticals' Interest Expenses (Quarter) stood at $2.8 million in 2022, then soared by 88.38% to $5.4 million in 2023, then soared by 303.32% to $21.6 million in 2024, then increased by 3.97% to $22.5 million in 2025.
  • Its Interest Expenses was $22.5 million in Q4 2025, compared to $21.7 million in Q3 2025 and $24.4 million in Q2 2025.